Measurable disease according to RECIST criteria (Version .)
Dose Escalation: Evaluable or measurable disease according to RECIST v. Expansion Cohort (additional  patients) Measurable disease according to RECIST v..
Subject must have measurable neoplastic disease according to the RECIST v.;
Measurable disease according to RECIST Version .
Measurable disease according to RECIST version (v). and obtained by imaging within  days prior to registration for protocol therapy; NOTE: A subject with prior brain metastasis may be considered if they comply with inclusion criteria below
Subjects must have measurable lesions (according to standard RECIST .).
Disease must be measurable according to the corresponding guidelines
Phase II only: Measurable disease according to RECIST v. (Section ) obtained by imaging within  days prior to study registration. Phase Ib: subjects may enroll with or without measurable disease.
Subject has measurable disease according to RECIST v. criteria prior to lymphodepletion
Measurable disease according to RECIST v. (must be outside central nervous system (CNS))
Measurable tumor lesions according to RECIST . criteria (Section .).
PHASE IB: Measurable disease according to RECIST v.
Measurable disease, according to RECIST, v.
Patients must have measurable disease according to RECIST .
Measurable or non-measurable disease according to RECIST v. or RECIL .
Metastatic and/or unresectable (cTb) urothelial cancer. Measurable disease according to RECIST . within  days prior to registration.
Measurable disease according to RECIST ..
Subjects must have measurable disease according to RECIST (version .)
Histologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version ..
Measurable or non-measurable disease according to RECIST v. or RECIL .
Measurable disease according to RECIST v. within  days prior to randomization
Subject has measurable disease according to RECIST v. criteria prior to lymphodepletion
Measurable disease according to RECIST . within  days prior to registration.
Subject has measurable disease according to RECIST v. criteria prior to lymphodepletion.
Measurable disease according to RECIST ..
Measurable disease, according to modified RECIST . and irRECIST
Patients must have measurable disease according to RECIST .
Measurable tumor lesions according to RECIST . criteria.[]
Subject has measurable disease according to RECIST v. and has relapsed or is refractory to prior therapy.
Measurable or non-measurable disease according to RECIST v. or RECIL .
Measurable tumor lesions according to RECIST . criteria.
Patient with measurable disease according to RECIST
Measurable disease according to RECIST v..
Measurable disease according to RECIST . within  days prior to registration.
Measurable disease according to RECIST Version .
At least one measurable site of disease in the liver according to RECIST version . and mRECIST criteria
Presence of measurable disease according to RECIST .
Patients must have measurable disease according to RECIST .
Measurable disease according to RECIST v.
Patients must have measurable disease according to RECIST (v..).
Radiologically measurable disease according to RECIST v.
Subject must have either measurable disease or bone only non measurable disease, according to RECIST.
Measurable disease according to RECIST v.
Measurable disease according to RECIST version ..
Measurable disease according to RECIST . criteria.
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) .; previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation; the pleural mesothelioma cohort will require measurable disease according to modified RECIST
Measurable disease according to RECIST v.
Measurable disease is required for Part B expansion cohorts according to RECIST v. criteria.
Demonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version . is NOT required for enrollment)
Measurable disease, according to the RECIST v.
Non-measurable disease according to RECIST ., with the exception of bone-only non-measurable disease.
Patients must have at least one measurable site of disease (according to RECIST [version .] criteria)
Patients must have at least one measurable site of disease according to RECIST version . criteria
Measurable disease according to RECIST ..
Have measurable disease according to RECIST v. obtained by imaging within  days prior to registration.
Measurable disease according to the RECIST criteria (version .), for the evaluation of measurable disease
Measurable disease according to modified RECIST version .
Measurable disease according to RECIST .
Measurable disease according to RECIST version .
Measurable disease according to RECIST v.
Measurable disease according to RECIST v . obtained by imaging within  days prior to registration
Measurable disease according to RECIST .
Subjects may have measurable or non-measurable disease according to RECIST ..
Measurable disease according to RECIST criteria (Version .)
Patients must have measurable disease according to RECIST ., and have relapsed or become refractory to conventional therapy
Measurable disease defined as one or more target lesions according to RECIST
Measurable tumor lesions according to RECIST . criteria.[]
Measurable radiographic evidence of disease according to RECIST v.
Measurable disease according to RECIST v. prior to administration of study drug
Measurable disease according to RECIST v.
Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors
Measurable disease according to RECIST
Measurable disease according to RECIST version ..
Measurable disease according to RECIST and obtained by imaging within  days prior to registration for protocol therapy.
Subject has measurable disease according to RECIST v. criteria.
Measurable disease according to RECIST v. criteria
Measurable disease according to RECIST v.
Measurable disease according to RECIST . criteria.
The participant has measurable or non-measurable disease according to RECIST . guidelines.
